Imdelltra (tarlatamab)
Research Synopsis
- - Tarlatamab (Imdelltra) is a bispecific T-cell engager targeting DLL3, showing promise for treating small cell lung cancer (SCLC) and neuroendocrine prostate cancer, especially in patients whose disease has progressed following prior therapy.
- - A phase I study reported a 23.4% objective response rate and a median duration of response of 12.3 months among patients with relapsed/refractory SCLC, indicating its potential as a viable treatment option.
- - Recent phase II trials demonstrated an improved objective response rate of 40% in patients receiving tarlatamab, alongside manageable side effects, including cytokine-release syndrome.
- - The promising results in SCLC have led to its FDA approval in May 2024 for adults with extensive-stage SCLC who have experienced disease progression after platinum-based chemotherapy.
- - Tarlatamab's efficacy is notably highlighted by its effectiveness in patients with high DLL3 expression, further validating DLL3 as a critical target for immunotherapy in aggressive cancer subtypes.
- - Comparative analysis revealed that while tarlatamab has shown significant potential, previous DLL3-targeting therapies like rovalpituzumab tesirine faced challenges, emphasizing the need for careful patient selection and combination therapy strategies.
- - Ongoing clinical trials will continue to assess the safety and efficacy of tarlatamab and other DLL3-targeted therapies, suggesting a focus on enhancing treatment strategies for SCLC in the future.
- - Researchers are optimistic that tarlatamab will open avenues for new therapeutic approaches, with a focus on precision therapy to improve outcomes for patients suffering from this aggressive form of lung cancer.
- - The latest findings in the DeLLphi trials indicate sustained therapeutic benefits, including intracranial activity in patients with existing brain metastases, marking an important advancement in SCLC treatment.
- - Overall, tarlatamab represents a significant step forward in addressing the unmet need for effective therapies in small cell lung cancer, demonstrating both clinical efficacy and providing a platform for further research and development in targeted cancer therapies.
Imdelltra (tarlatamab)
Harnessing DLL3 inhibition: From old promises to new therapeutic horizons.
London, UK
2 hours ago
1 Received
- Small-cell lung cancer (SCLC) is a fast-growing and challenging type of lung cancer with a high chance of coming back after treatment and few effective therapies available.
- *The introduction of chemotherapy combined with immune-checkpoint inhibitors marks a potential breakthrough, but there’s a challenge due to the absence of predictive biomarkers that can identify which patients will benefit most.
- *Delta-like canonical Notch ligand 3 (DLL3) is often found in high levels in SCLC, making it a target for new treatments; the article reviews existing DLL3 inhibitors and discusses the potential of new compounds based on updated molecular classifications of SCLC.
$100 - $150
Hourly Rate
Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.
London, UK
2 hours ago
1 Received
- Effective treatments for small-cell/neuroendocrine prostate cancer (t-SCNC) are lacking, but DLL3 is identified as a key marker associated with poor survival rates in these patients.
- Researchers developed a PET agent to detect DLL3 and found that the immunotherapy AMG 757 effectively targets and kills DLL3-expressing cancer cells in preclinical models.
- Clinical trials are underway for AMG 757, showing promising results, including a partial response in a patient, highlighting DLL3 as a viable therapeutic target in aggressive prostate cancer subtypes.
$100 - $150
Hourly Rate
Taking it up a notch: a promising immunotherapy against small cell lung cancer.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
London, UK
2 hours ago
1 Received
- Tarlatamab (AMG 757) is a new treatment for small-cell lung cancer (SCLC) that targets DLL3 and CD3, leading to tumor destruction through T-cell activation.
- In a phase I study involving 107 patients with relapsed/refractory SCLC, results showed a 23.4% objective response rate, with manageable safety issues and a median duration of response of 12.3 months.
- The findings indicate that tarlatamab may be a promising treatment option for heavily pretreated SCLC patients, warranting further research, especially in patients with higher DLL3 expression.
$100 - $150
Hourly Rate
Tarlatamab: New Star on the Horizon for Small-Cell Lung Cancer?
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.
London, UK
2 hours ago
1 Received
- * DLL3 is a promising target for SCLC treatment since it is largely overexpressed in cancer cells but minimally present in normal cells; research is ongoing into various DLL3-targeted therapies like antibody-drug conjugates, T-cell engagers, and CAR T-cell therapies.
- * The clinical failure of a DLL3-targeting treatment called rovalpituzumab tesirine (Rova-T) highlights the need for continued development and refinement of DLL3-targeting strategies, focusing on patient selection and combination therapies to improve effectiveness.
$100 - $150
Hourly Rate
Tarlatamab: the promising immunotherapy on its way from the lab to the clinic.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Tarlatamab: a potential new option for recurrent small cell lung cancer.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
London, UK
2 hours ago
1 Received
- Tarlatamab is a bispecific T-cell engager immunotherapy that showed promising results in a phase 1 trial for patients with previously treated small-cell lung cancer.
- In a phase 2 trial involving 220 patients, tarlatamab was administered intravenously every 2 weeks at doses of 10 mg or 100 mg, with an objective response rate of 40% and 32% respectively.
- The study found that common side effects included cytokine-release syndrome, decreased appetite, and fever, with overall survival rates at 9 months being 68% for the 10-mg group and 66% for the 100-mg group.
$100 - $150
Hourly Rate
Tarlatamab Shows Promise in SCLC.
London, UK
2 hours ago
1 Received
- - Tarlatamab is a new bispecific T-cell engager designed to target the delta-like ligand 3 protein, showing effectiveness in small cell lung cancer patients who've exhausted other treatment options.
- - The drug has demonstrated encouraging results in improving the condition of these patients, indicating its potential as a treatment alternative.
- - However, there are concerns regarding the method of administration, leading to uncertainty about its acceptance and use among clinicians and patients.
$100 - $150
Hourly Rate
Second-Line Treatment Options for Small-Cell Lung Cancer: A Light at the End of the Tunnel.
London, UK
2 hours ago
1 Received
- - Small-cell lung cancer (SCLC) is a fast-growing type of lung cancer, making up about 15% of cases, with most patients already having advanced disease at diagnosis.
- - Standard first-line treatment is chemo-immunotherapy, but most patients relapse, leading to ongoing research into second-line therapies, which currently have limited success.
- - Promising new treatments, including antibodies targeting PD-1, PD-L1, and DLL3, are being investigated, with Tarlatamab showing potential for previously treated patients.
$100 - $150
Hourly Rate
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy.
London, UK
2 hours ago
1 Received
- * Various therapies targeting DLL3 include antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), and CAR T-cell therapies, with tarlatamab showing promising results and currently under FDA review.
- * Ongoing clinical trials are set to assess the effectiveness of DLL3-targeted therapies, including novel T-cell engagers and radiotherapy, emphasizing the need for further research to improve treatment outcomes for SCLC patients.
$100 - $150
Hourly Rate
The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics.
London, UK
2 hours ago
1 Received
- Small cell lung cancer (SCLC) is an aggressive type of lung cancer that represents 15% of cases and has not seen significant treatment advancements in the past 40 years, leading to poor survival rates.
- Recent treatment strategies for extensive-stage SCLC have included immune checkpoint inhibitors alongside traditional chemotherapy, resulting in only slight improvements in patient outcomes.
- Advances in molecular research have revealed that SCLC is heterogeneous at both molecular and genetic levels, which could unlock new therapeutic targets and improve treatment options moving forward.
$100 - $150
Hourly Rate
Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients.
London, UK
2 hours ago
1 Received
- Small cell lung cancer (SCLC) has a very low 5-year survival rate of less than 7%, even with the inclusion of new immunotherapy treatments alongside chemotherapy.
- Specific biomarkers like DLL3 and SLFN11 could help identify more effective targeted therapies, such as bispecific monoclonal antibodies and PARP inhibitors.
- The use of circulating tumor cells (CTCs) from blood tests presents a potentially easier approach for gaining insights into SCLC and guiding treatment decisions, but their effectiveness for this purpose is still being researched.
$100 - $150
Hourly Rate
Tarlatamab (Imdelltra) for small cell lung cancer.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Tarlatamab: First Approval.
London, UK
2 hours ago
1 Received
- Tarlatamab (IMDELLTRA™) is a novel bispecific T-cell engager developed by Amgen for treating small cell lung cancer (SCLC) and neuroendocrine prostate cancer, designed to activate T-cells against tumor cells expressing DLL3.
- In May 2024, it received initial approval in the USA for adults with extensive stage SCLC whose disease progressed after platinum-based chemotherapy, based on positive results from the DeLLphi-301 study.
- The drug is currently under regulatory review in several countries, including Brazil, Canada, Israel, and the UK, with ongoing clinical studies to further assess its benefits.
$100 - $150
Hourly Rate
Tarlatamab-dlle: A New Hope for Patients with Extensive-Stage Small-Cell Lung Cancer.
London, UK
2 hours ago
1 Received
- * The survival rate for SCLC is only 5-10% over five years, with extensive-stage cases showing rare long-term disease-free survival.
- * In May 2024, the FDA approved Tarlatamab-dlle, a new treatment targeting DLL3 for extensive-stage SCLC, which follows the previous approvals of a few other drugs, raising some unanswered questions about its rapid approval.
$100 - $150
Hourly Rate
Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update.
London, UK
2 hours ago
1 Received
- Tarlatamab, an immunotherapy targeting delta-like ligand 3, shows promising anticancer effects in small cell lung cancer (SCLC) based on the DeLLphi-300 and DeLLphi-301 trials, with manageable safety profiles.
- In the extended follow-up of DeLLphi-300, the overall response rate was 25%, with a median duration of response of 11.2 months and a median overall survival of 17.5 months across 152 patients.
- Among those receiving a specific dose regimen (10 mg every two weeks), 35.3% experienced a response, and notable intracranial tumor shrinkage was found in patients with existing brain lesions, highlighting tarlatam
$100 - $150
Hourly Rate
Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report.
London, UK
2 hours ago
1 Received
- - A 20-year-old man with advanced lung cancer, specifically metastatic large cell neuroendocrine carcinoma, received treatment with tarlatamab, a bispecific T cell engager targeting delta-like ligand 3.
- - The treatment led to temporary cytokine release syndrome, which is an inflammatory response, but ultimately resulted in a partial improvement in his symptoms.
- - Tarlatamab and similar bispecific T cell engagers could represent a new way to treat this type of lung cancer.
$100 - $150
Hourly Rate
'Tarlatamab's FDA approval: shaping the future of cancer therapy'.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate